Bevacizumab for Refractory Solid Tumors in Pediatric Patients
- 28 March 2008
- journal article
- Published by Taylor & Francis in Pediatric Health
- Vol. 2 (2) , 147-149
Abstract
Evaluation of: Bender JL, Adamson PC, Reid JM et al.: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. J. Clin. Oncol. 26, 399–405 (2008). Angiogenesis is important for both tumor growth and development of metastases. Vascular endothelial growth factor is a potent proangiogenic factor. Bevacizumab, a humanized antibody against vascular endothelial growth factor is currently being tested for various malignancies among adult cancer patients, but has not yet been prospectively evaluated in children and young adults with malignant solid tumors. The results of the first Phase I trial of bevacizumab in this population are here presented by Bender et al. Bevacizumab administered at 5, 10 and 15 mg/kg doses every 2 weeks was well tolerated with no major toxicities (i.e., hemorrhage or thrombosis) observed. None of the patients achieved an objective response. Trials assessing combinations of bevacizumab with cytotoxic chem...Keywords
This publication has 12 references indexed in Scilit:
- Challenges in prescribing drugs for children with cancerThe Lancet Oncology, 2008
- Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future DirectionsClinical Cancer Research, 2007
- Combining chemotherapy and targeted therapies in metastatic colorectal cancerWorld Journal of Gastroenterology, 2007
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A reviewEuropean Journal of Cancer, 2006
- Trends in survival after childhood cancer in Europe, 1978–1997: Report from the Automated Childhood Cancer Information System project (ACCIS)European Journal of Cancer, 2006
- Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerSeminars in Oncology, 2003